Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Curative Biotechnology, Inc. (OTC: CUBT) is a development-stage biomedical company focused on novel therapies for rare diseases, with programs in degenerative eye disease, infectious disease, and neuro-oncology. The CUBT news feed on this page aggregates company-issued updates and other coverage so readers can follow how its pipeline and strategy evolve over time.
Recent news has highlighted Curative Biotech’s emphasis on its degenerative eye disease platform, built on a worldwide exclusive license from the National Eye Institute (NEI) at the NIH. Articles cover progress with its metformin-based ophthalmic reformulation for intermediate and late-stage Age-Related Macular Degeneration (AMD), including completion of IND-enabling toxicology work, a planned first-in-human trial under a CRADA with the NEI, and the filing of a PCT patent application for an ophthalmic formulation capable of delivering metformin to the choroid, RPE, and retina.
News items also describe corporate and strategic developments, such as the establishment of Curative Biotech Japan K.K. to support licensing and asset acquisitions in Japan, the engagement of Golden Eagle Capital Advisors, Inc. as exclusive agent and strategic advisor, and updates on capital structure, including withdrawal of a planned S-1 offering and revisions to a proposed reverse stock split. Governance-focused releases detail the nomination or appointment of independent directors with ophthalmology and biotechnology experience and the creation of a Clinical Development Committee of the Board.
Investors and observers can use this page to review Curative Biotech’s announcements on clinical planning, licensing strategy, veterinary ophthalmology initiatives in canine retinal diseases, and capital markets intentions, all in one place. Bookmark this feed to quickly reference historical and ongoing CUBT news as the company advances its development-stage programs.
Curative Biotechnology (OTC: CUBT) engaged Sterling Pharmaceutical Services to manufacture clinical supply of a metformin-based topical ophthalmic formulation, advancing toward a planned first-in-human Phase 1 study in dry Age-Related Macular Degeneration (AMD) and a clinical K9 PDE6 retinal degeneration study.
The work supports the Company’s CRADA with NIH and follows Curative’s 1-for-150 reverse stock split as it pursues an uplist to the OTCQB Venture Market.
Curative Biotechnology (CUBT, temporarily CUBTD) executed a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and DTC-eligible shares from ~266.8 million to ~1.78 million. The company's ticker will show as CUBTD for 20 trading days.
Curative plans manufacturing to begin mid-April 2026, received a U.S. manufacturer proposal for sterile metformin ophthalmic drops, intends a Phase 1 NIH CRADA human study for dry AMD, and will pursue an OTCQB uplisting after a manufacturing agreement.
Curative Biotechnology (OTC: CUBT) implemented a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and temporarily changing its ticker to CUBTD for 20 trading days.
The company received a U.S. manufacturing proposal to produce sterile metformin ophthalmic drops, plans manufacturing to begin mid-April 2026, intends a first-in-human Phase 1 study under an NIH CRADA for dry AMD, and aims to pursue an OTCQB uplist after executing a manufacturing and product development agreement.
Curative Biotechnology (OTC: CUBT) announced that the Canadian Intellectual Property Office issued a Notice of Allowance for Canadian Patent Application No. 3,151,011 titled “Druggable Target to Treat Retinal Degeneration.” Curative is the exclusive worldwide licensee under an agreement with the National Eye Institute, and the invention was developed by Dr. Kapil Bharti and team. The allowance includes 22 allowed claims covering topical ocular delivery approaches relevant to metformin-based formulations and is expected to formally issue in the coming months. The company also noted parallel development into select canine retinal indications such as PRA and PRCD.
Curative Biotechnology (OTC: CUBT) announced a strategic redirection focused on sublicensing and manufacturing partnerships, a revised reverse stock split, and withdrawal of a planned S-1 public offering.
Key actions: pursuing a sublicence/manufacturing agreement for its metformin-based eye drops; targeting simultaneous human Dry AMD and canine indications (CPRA with a single 24-dog accelerated trial; PRA with ~300-dog effectiveness trial); withdrawing the S-1; and approving a 150-to-1 reverse split (replacing 400-to-1) pending FINRA approval. The company also plans to apply to uplist to the OTCQB after the sublicense and reverse split.
Curative Biotechnology (OTC: CUBT), a development-stage biomedical company specializing in treatments for degenerative eye diseases, has announced the appointment of Golden Eagle Capital Advisors (GECA) as its exclusive agent and strategic advisor. GECA, a Dubai-based financial advisory group, will provide strategic guidance to support CUBT's business objectives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.